Open Federal Grants · National Institutes of Health
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
National Institutes of Health · Opportunity PAR-25-297 · Awards up to $1,500,000
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-b
Eligibility text quoted from the official Grants.gov listing.
About This Opportunity
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, …
Description from the official Grants.gov listing — read the complete notice, including any updates, on Grants.gov before applying.
More Open Grants From NIH
Browse Open Grants
By who can apply:
By agency:
By closing month:
Every grant listed here comes from Grants.gov, the official U.S. government database. Award amounts and deadlines can change — verify the details on the official listing before you apply. GrantRound is not affiliated with the U.S. government.